| Abstrakt: |
As a result, as the research develops, the tyrosine kinase inhibitor therapeutic drug monitoring classification needs to be refined in terms of factors like sex and age." According to news originating from Orbassano, Italy, by NewsRx correspondents, research stated, "Tyrosine kinase inhibitors work by blocking the tyrosine kinases responsible for the dysregulation of intracellular signalling pathways in tumour cells." Keywords: Amino Acids; Antineoplastics; Aromatic Amino Acids; BCR-ABL Tyrosine Kinase Inhibitors; Cancer; Chronic Myeloid Leukemia; Dasatinib Therapy; Drugs and Therapies; Enzymes and Coenzymes; Health and Medicine; Hematology; Imatinib Therapy; Kinase; Leukemia; Myeloid Leukemia; Oncology; Pediatrics; Pharmaceuticals; Pharmacokinetics; Pharmacology; Protein Kinase Inhibitors; Proteins; Proteomics; Sprycel Therapy; Tyrosine; Tyrosine Kinase; Tyrosine Kinase Inhibitors EN Amino Acids Antineoplastics Aromatic Amino Acids BCR-ABL Tyrosine Kinase Inhibitors Cancer Chronic Myeloid Leukemia Dasatinib Therapy Drugs and Therapies Enzymes and Coenzymes Health and Medicine Hematology Imatinib Therapy Kinase Leukemia Myeloid Leukemia Oncology Pediatrics Pharmaceuticals Pharmacokinetics Pharmacology Protein Kinase Inhibitors Proteins Proteomics Sprycel Therapy Tyrosine Tyrosine Kinase Tyrosine Kinase Inhibitors 2281 2281 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on chronic myeloid leukemia have been published. [Extracted from the article] |
